

**ANTICANCER AGENT TREAKISYM[®] APPROVED IN JAPAN FOR
ADDITIONAL INDICATION AS FIRST-LINE TREATMENT FOR LOW-GRADE B-CELL
NON-HODGKIN'S LYMPHOMA AND MANTLE CELL LYMPHOMA**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the anticancer agent TREAKISYM[®] (generic name: bendamustine hydrochloride) has been approved in Japan for an additional indication as first-line treatment for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma (MCL)-

[Notes to editors]

1. About bendamustine hydrochloride (generic name, product name: TREAKISYM for injection 25 mg, 100 mg)

Bendamustine hydrochloride is an anticancer agent originally synthesized by